Skip to content

To compare which treatment option is better in Tennis Elbow patients Platelet Rich Plasma (PRP) injection or Steroid (Triamcinolone acetate) injection

Comparison of Effectiveness of injection Triamcinolone Acetate vs Platelet Rich Plasma (PRP) in management of Lateral Epicondylitis (Tennis Elbow) Patients A Randomized controlled trail - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/100100
Enrollment
64
Registered
2026-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M771- Lateral epicondylitis

Interventions

Intervention1: Injection Triamcinolone Acetate : 40mg at most tender point around ECRB tendon Duration for 9 months Intervention2: Injection Platelet Rich Plasma: 1ml at most tender point inside ECRB

Sponsors

AIIMS JAMMU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants were included if they met the following criteria: 1. Diagnosis of chronic lateral epicondylitis of the elbow based on clinical examination. This was defined by: a. Pain on palpation of the lateral epicondyle, and b. Pain during resisted wrist extension or supination of the forearm. 2. Symptoms lasting at least 6 months.3. Failure of conservative treatment, including physiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and rest. 4. Age between 18 and 60 years. 5. No previous injections at the affected elbow. 6. Patient consent to participate in the study.

Exclusion criteria

Exclusion criteria: Participants were excluded if they presented with any of the following: 1. Bilateral elbow symptoms. 2. Involvement of the cervical spine or shoulder (which could refer pain to the elbow). 3. Rheumatoid arthritis or other inflammatory arthropathy. 4. Coagulopathy (blood clotting disorder). 5. Prior surgery on the affected elbow. 6. Chronic use of corticosteroids.

Design outcomes

Primary

MeasureTime frame
Pain intensity: VAS score (0-10)Timepoint: At Baseline, 1,3,6 months followup

Secondary

MeasureTime frame
Functional Disability: PRTEE (0-100) Adverse events: incidence and severity recorded at each follow upTimepoint: At Baseline, 1,3,6 months followup

Countries

India

Contacts

Public ContactDr Amit Thakur

AIIMS JAMMU

Amit.thakur@aiimsjammu.edu.in184120

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026